IL252046D0 - Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels - Google Patents

Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Info

Publication number
IL252046D0
IL252046D0 IL252046A IL25204617A IL252046D0 IL 252046 D0 IL252046 D0 IL 252046D0 IL 252046 A IL252046 A IL 252046A IL 25204617 A IL25204617 A IL 25204617A IL 252046 D0 IL252046 D0 IL 252046D0
Authority
IL
Israel
Prior art keywords
red blood
blood cell
combined use
cell levels
erythropoietin receptor
Prior art date
Application number
IL252046A
Other languages
Hebrew (he)
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/583,177 priority Critical patent/US8058229B2/en
Priority to PCT/US2009/004659 priority patent/WO2010019261A1/en
Priority to US30590110P priority
Priority to PCT/US2010/045509 priority patent/WO2011020045A1/en
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of IL252046D0 publication Critical patent/IL252046D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
IL252046A 2008-08-14 2017-05-01 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels IL252046D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/583,177 US8058229B2 (en) 2008-08-14 2009-08-13 Method of increasing red blood cell levels or treating anemia in a patient
PCT/US2009/004659 WO2010019261A1 (en) 2008-08-14 2009-08-13 Use of gdf traps to increase red blood cell levels
US30590110P true 2010-02-18 2010-02-18
PCT/US2010/045509 WO2011020045A1 (en) 2009-08-13 2010-08-13 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Publications (1)

Publication Number Publication Date
IL252046D0 true IL252046D0 (en) 2017-06-29

Family

ID=43586530

Family Applications (4)

Application Number Title Priority Date Filing Date
IL218052A IL218052A (en) 2008-08-14 2012-02-12 Use of erythropoietin receptor activator and a polypeptide in the preparation of medicaments for combined administration for increasing red blood cell levels or treating or preventing anemia
IL252046A IL252046D0 (en) 2008-08-14 2017-05-01 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
IL252044A IL252044D0 (en) 2008-08-14 2017-05-01 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
IL252045A IL252045D0 (en) 2008-08-14 2017-05-01 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL218052A IL218052A (en) 2008-08-14 2012-02-12 Use of erythropoietin receptor activator and a polypeptide in the preparation of medicaments for combined administration for increasing red blood cell levels or treating or preventing anemia

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL252044A IL252044D0 (en) 2008-08-14 2017-05-01 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
IL252045A IL252045D0 (en) 2008-08-14 2017-05-01 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Country Status (13)

Country Link
EP (2) EP3117829A1 (en)
JP (3) JP5909446B2 (en)
KR (2) KR101882521B1 (en)
CN (4) CN102655872B (en)
AU (1) AU2010282361B2 (en)
BR (1) BR112012003232A2 (en)
CA (1) CA2770822A1 (en)
HK (2) HK1223818A1 (en)
IL (4) IL218052A (en)
MX (1) MX2012001916A (en)
NZ (3) NZ712943A (en)
RU (3) RU2642302C1 (en)
WO (1) WO2011020045A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3489257A1 (en) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
CA2631013C (en) 2005-11-23 2019-06-11 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
KR20140137463A (en) 2007-02-01 2014-12-02 악셀레론 파마 인코포레이티드 Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201803890A (en) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 Variants derived from ActRIIB and uses therefor
BRPI0807506A2 (en) 2007-02-09 2013-07-30 Acceleron Pharma Inc activin-actria antagonist and uses for promoting bone growth in cancer patients
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK2340031T3 (en) 2008-08-14 2019-07-15 Acceleron Pharma Inc Gdf customer for use of analysis treatment
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
EP3345921A1 (en) 2009-06-08 2018-07-11 Acceleron Pharma Inc. Use of anti-actriib antibodies for increasing thermogenic adipocytes
KR20190090049A (en) 2009-06-12 2019-07-31 악셀레론 파마 인코포레이티드 TRUNCATED ActRIIB-FC FUSION PROTEINS
ES2658292T3 (en) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses thereof with respect to the induction of utrophin for the treatment of muscular dystrophy
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
CN107693776A (en) * 2011-10-17 2018-02-16 阿塞勒隆制药公司 Methods and compositions for treating ineffective erythropoiesis
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
EP2911682A4 (en) * 2012-10-24 2016-03-23 Celgene Corp Methods for treating anemia
JP6401171B2 (en) * 2012-10-24 2018-10-03 セルジーン コーポレイション Biomarkers for use in the treatment of anemia
CA2890217A1 (en) 2012-11-02 2014-05-08 Yifu FANG Activin-actrii antagonists and uses for treating bone and other disorders
WO2015143403A1 (en) * 2014-03-21 2015-09-24 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11
AU2015274277A1 (en) * 2014-06-13 2016-12-01 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
JP2017533910A (en) * 2014-10-30 2017-11-16 アクセルロン ファーマ, インコーポレイテッド Methods and compositions for increasing red blood cells using GDF35 polypeptides
WO2016090188A1 (en) * 2014-12-03 2016-06-09 Acceleron Pharma Inc. Methods for treating myelodysplastic syndromes and sideroblastic anemias
MD20180012A2 (en) * 2014-12-03 2018-05-31 Celgene Corporation Activin-ActRII antagonists and uses for treating anemia
WO2016128523A1 (en) * 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
EP3370754A2 (en) * 2015-11-04 2018-09-12 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology Method for enhancing glycoprotein stability.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
CA2217545A1 (en) 1995-04-11 1996-10-17 Marc Vidal Reverse two-hybrid systems
DE60027135T2 (en) 1999-01-21 2007-01-11 Metamorphix, Inc. Inhibitors of growth differentiation factor and its applications
CN1309416C (en) * 2000-05-15 2007-04-11 霍夫曼-拉罗奇有限公司 Pharmaceutical composition
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
EP2289531B1 (en) * 2001-12-06 2018-07-04 Fibrogen, Inc. Medicaments for the treatment or prevention of anemia
DE10234192B4 (en) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Use of erythropoietin
ZA200506246B (en) * 2003-02-07 2006-12-27 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
GB0304424D0 (en) * 2003-02-26 2003-04-02 Glaxosmithkline Biolog Sa Novel compounds
EP3489257A1 (en) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US20070003576A1 (en) * 2004-12-09 2007-01-04 Andrea Gambotto Vaccines for the rapid response to pandemic avian influenza
JPWO2006115274A1 (en) * 2005-04-26 2008-12-18 味の素株式会社 Bone marrow erythroid progenitor cell differentiation promoting agent
JP5361386B2 (en) * 2005-10-07 2013-12-04 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Matrix metalloproteinase 11 vaccine
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100003190A1 (en) * 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
NZ577847A (en) * 2006-12-18 2012-06-29 Acceleron Pharma Inc Activin-actrii antagonists and uses for increasing red blood cell levels
TW201803890A (en) * 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 Variants derived from ActRIIB and uses therefor
CA3049354A1 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
DK2340031T3 (en) * 2008-08-14 2019-07-15 Acceleron Pharma Inc Gdf customer for use of analysis treatment

Also Published As

Publication number Publication date
IL252045D0 (en) 2017-06-29
JP2013501816A (en) 2013-01-17
CN105561295A (en) 2016-05-11
EP2464369A4 (en) 2013-07-17
KR20120054024A (en) 2012-05-29
HK1223818A1 (en) 2017-08-11
WO2011020045A1 (en) 2011-02-17
KR20180085825A (en) 2018-07-27
CN102655872A (en) 2012-09-05
AU2010282361B2 (en) 2015-03-19
IL218052A (en) 2017-05-29
RU2642302C1 (en) 2018-01-24
JP2018177816A (en) 2018-11-15
RU2017145301A3 (en) 2019-06-24
AU2010282361A1 (en) 2012-03-15
RU2017145301A (en) 2019-06-24
NZ712943A (en) 2017-08-25
NZ623113A (en) 2015-10-30
NZ598348A (en) 2014-05-30
CN105535938A (en) 2016-05-04
IL218052D0 (en) 2012-04-30
CN102655872B (en) 2016-01-20
HK1224199A1 (en) 2017-08-18
CN105412908A (en) 2016-03-23
BR112012003232A2 (en) 2016-11-22
KR101882521B1 (en) 2018-07-27
JP2016034981A (en) 2016-03-17
IL252044D0 (en) 2017-06-29
MX2012001916A (en) 2012-05-22
JP5909446B2 (en) 2016-04-26
EP3117829A1 (en) 2017-01-18
RU2592670C2 (en) 2016-07-27
WO2011020045A9 (en) 2011-06-03
EP2464369A1 (en) 2012-06-20
CA2770822A1 (en) 2011-02-17
RU2012109393A (en) 2013-09-20

Similar Documents

Publication Publication Date Title
GB2502236B (en) Indications of cross-section of small branched blood vessels
DK2646444T3 (en) Substituted purin and 7-deazapur compounds as modulators of epigenetic enzymes
LT2750682T (en) Composition comprising anaerobically cultivated human intestinal microbiota
EP2618881A4 (en) Catheter electrode assemblies and methods of construction therefor
HK1176721A1 (en) Background migration of virtual storage
PL2923688T3 (en) Assembly to facilitate user reconstitution
PL2424356T3 (en) Stable pharmaceutical composition and methods of using same
LT3040424T (en) Modified proteins and methods of making and using same
EP2625624A4 (en) Distribution of content and behavior to disparate platforms
BRPI0815052A2 (en) Differentiation of pluripotent stem cells by human nutrie cell use
ZA201304153B (en) Anti-pcsk9 antibodies and methods of use
EP2280741A4 (en) Irreversible electroporation to create tissue scaffolds
PL2611907T3 (en) Differentiation of pluripotent stem cells
HK1207640A1 (en) Arylalkyl esters of 4-aminopicolinates and their use as herbicides 4-
PL2283114T3 (en) Treatment of pluripotent cells
PT2652897T (en) Exchange of parameters relating to measurement periods
GB201202848D0 (en) Differemtiaiotn of human embryonic stem cells
IL216810D0 (en) Catheter with sheet array of electrodes
EP2456466A4 (en) Adhesive complex coacervates and methods of making and using thereof
EP2522002A4 (en) Determination of time zone and dst participation
EP2642937A4 (en) Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
ZA201209383B (en) Differentiation of human embryonic stem cells
PT2582242T (en) Combinations of active substances with insecticidal and acaricidal properties
EP2661264A4 (en) Melanin modification compositions and methods of use
HK1166884A1 (en) Design and construction of non-rectangular batteries